Generic Epzicom Availability
EPZICOM (abacavir sulfate; lamivudine - tablet;oral)
Manufacturer: VIIV HLTHCARE
Approval date: August 2, 2004
Strength(s): EQ 600MG BASE;300MG [RLD]
Has a generic version of Epzicom been approved?
No. There is currently no therapeutically equivalent version of Epzicom available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Epzicom. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Crystalline oxathiolane derivatives
Issued: May 18, 1999
Inventor(s): Roberts; Tony Gordon & Evans; Paul
Assignee(s): Glaxo Group Limited
(-)cis-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(IH)-pyrimidine-2-on e in crystalline form, in particular as needle-shaped or bypyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.Patent expiration dates:
- May 18, 2016✓✓
- November 18, 2016✓
- May 18, 2016
Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Issued: September 25, 2001
Inventor(s): Brodie; Alastair Couper & Jones; Martin Francis & Seager; John Frederick & Wallis; Christopher John
Assignee(s): Glaxo Wellcome Inc.
The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.Patent expiration dates:
- May 14, 2018✓✓✓
- November 14, 2018✓
- May 14, 2018
Synergistic combinations of zidovudine, 1592U89 and 3TC
Issued: July 9, 2002
Inventor(s): David Walter; Barry & Martha Heider; St. Clair
The present invention relates to therapeutic combinations of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol (1592U89), 3′-azido-3′-deoxythymidine (zidovudine) and (2R,cis)-4-amino-]-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (FTC)) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.Patent expiration dates:
- March 28, 2016✓✓
- September 28, 2016✓
- March 28, 2016
- Epzicom Consumer Information (Drugs.com)
- Epzicom Consumer Information (Wolters Kluwer)
- Epzicom Consumer Information (Cerner Multum)
- Epzicom Advanced Consumer Information (Micromedex®)
- Abacavir/lamivudine Consumer Information (Wolters Kluwer)
- Abacavir and lamivudine Consumer Information (Cerner Multum)
- Abacavir and lamivudine Advanced Consumer Information (Micromedex®)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|